Intellicell Biosciences Inc (fka SVFC)

[Traderboy1966]

CPReports.com says IntelliCell's therapy "a game changer"
by Joyanta Acharjee
CPreports.com issued a report on IntelliCell BioSciences (OTCQB:SVFC) which called the company's Stromal Vascular Fraction (SVF) celluar therapy "a game changer" in the treatment of orthopedic and sports inflammatory conditions.
IntelliCell BioSciences is a regenerative medicine company focused on the expanding regenerative medical markets using stromal vascular fraction derived from adult fat tissue. It intends to initially focus on selling laboratory suites and licensing its technology to doctors for use in their offices for their patients.
In the research report, veteran Wall Street analyst Ray Dirks said Intellicell's SVF cell therapy was a thousand times more potent than the current therapy of cortisone for treating inflammation, but it also re-grows tissue, cartilage, and blood vessels.
"There is no other treatment on the market that has ever shown re-growth of tissue," Dirks said in his note.
Intellicell's therapy requires the taking of two ounces of fat tissue which is then broken down using ultrasonic cavitation, leaving only anti-inflammatory cells which are then re-injected back into the patient.
"The Intellicell procedure is much less invasive, much less painful, and it re-grows the damaged tissue and cartilage," Dirks said in his report.
The process is already being commercially used by doctors and is not considered a drug by the FDA so multi-year phase trials are not necessary.
Intellicell is planning a seven-center clinical study of approximately 300 patients under the direction of advisory board member Dr. James Andrews, who is the father, according to the report, of "Tommy John" surgery - a medical procedure that replaces a ligament in the elbow with a tendon from elsewhere, a common procedure among professional athletes.
A full page Daily News article, titled “Stem Sells” written by Sean Brennan published February 19, 2012, http://www.nydailynews.com/sports/college/manhattan-basketball-torgrim-sommerfeldt-turned-stem-cell-treatment-back-court-article-1.1025227, describes how Torgrim Sommerfeldt’s basketball career was saved through IntelliCell's proprietary SVF cell therapy.
There are several major baseball and American football teams that are in negotiations to purchase Intellicell lab facilities, Dirks said.
The company is also scheduled to open its first Centre of Excellence on Park Avenue in New York in April 2012. Dirks reckons this facility will be extremely profitable "out of the gate" with estimates of $20 million in revenue with a $10 million profit.
Intellicell also intends to license its technology for the treatment of heart as well as wound healing worldwide, which could lead to significant up-front cash fees that would energize the stock price.
After a recent capital raising, the company has projected to have $1.5 million of cash and no debt.
Independent research firm CPReports.com provides readers and subscribers with market commentary. Content is focused on what is going on in the stock market and on Wall Street.